

# Mariele Gatto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9101907/publications.pdf>

Version: 2024-02-01

97  
papers

6,591  
citations

117453

34  
h-index

64668

79  
g-index

101  
all docs

101  
docs citations

101  
times ranked

9745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autophagy in Human Health and Disease. <i>New England Journal of Medicine</i> , 2013, 368, 651-662.	13.9	2,188
2	Autophagy in Human Health and Disease. <i>New England Journal of Medicine</i> , 2013, 368, 1845-1846.	13.9	601
3	Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2117-2122.	0.5	181
4	Autoinflammation and autoimmunity: Bridging the divide. <i>Autoimmunity Reviews</i> , 2012, 12, 22-30.	2.5	178
5	Overlap connective tissue disease syndromes. <i>Autoimmunity Reviews</i> , 2013, 12, 363-373.	2.5	150
6	The clinical features, diagnosis and classification of dermatomyositis. <i>Journal of Autoimmunity</i> , 2014, 48-49, 122-127.	3.0	148
7	Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 104-110.	0.5	131
8	Galectin-3 in autoimmunity and autoimmune diseases. <i>Experimental Biology and Medicine</i> , 2015, 240, 1019-1028.	1.1	120
9	Changing patterns in clinical histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1318-1325.	0.5	119
10	New therapeutic strategies in systemic lupus erythematosus management. <i>Nature Reviews Rheumatology</i> , 2019, 15, 30-48.	3.5	118
11	Emerging and critical issues in the pathogenesis of lupus. <i>Autoimmunity Reviews</i> , 2013, 12, 523-536.	2.5	114
12	Optimizing outcome in SLE: treating-to-target and definition of treatment goals. <i>Autoimmunity Reviews</i> , 2014, 13, 770-777.	2.5	108
13	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.)	2.5	107
14	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 115-123.	1.5	107
15	Lupus nephritis: clinical presentations and outcomes in the 21st century. <i>Rheumatology</i> , 2020, 59, v39-v51.	0.9	100
16	Human papillomavirus vaccine and systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2013, 32, 1301-1307.	1.0	98
17	Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 267-280.	2.9	94
18	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 6-12.	3.0	89

#	ARTICLE	IF	CITATIONS
19	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018, 86, 1-8.	3.0	86
20	SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. <i>Journal of Autoimmunity</i> , 2020, 112, 102502.	3.0	86
21	Predictors of maternal and fetal complications in SLE patients: a prospective study. <i>Immunologic Research</i> , 2014, 60, 170-176.	1.3	84
22	The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 562-565.	0.5	83
23	Pregnancy and vasculitis: A systematic review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, A447-A459.	2.5	81
24	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 194-200.	3.0	80
25	Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease. <i>PLoS ONE</i> , 2013, 8, e71458.	1.1	79
26	IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. <i>Experimental Biology and Medicine</i> , 2019, 244, 42-51.	1.1	65
27	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020, 72, 1314-1324.	2.9	58
28	Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 856-63.	0.4	56
29	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 449-56.	0.4	55
30	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1077-1083.	0.5	49
31	Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. <i>Immunologic Research</i> , 2013, 56, 362-370.	1.3	46
32	Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review. <i>Journal of Autoimmunity</i> , 2016, 69, 1-11.	3.0	45
33	Role of galectin-3 in autoimmune and non-autoimmune nephropathies. <i>Autoimmunity Reviews</i> , 2017, 16, 34-47.	2.5	43
34	Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. <i>Journal of Autoimmunity</i> , 2016, 74, 94-105.	3.0	42
35	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1571-1580.	1.0	36
36	Advances in the diagnosis and classification of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1309-1320.	1.3	36

#	ARTICLE	IF	CITATIONS
37	Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 331-343.	2.9	34
38	Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. <i>Rheumatology</i> , 2020, 59, 1591-1598.	0.9	34
39	PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 217-226.	2.9	33
40	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 754-759.	0.4	33
41	Premature coronary heart disease in SLE: can we prevent progression?. <i>Lupus</i> , 2013, 22, 1232-1242.	0.8	31
42	Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. <i>Journal of Autoimmunity</i> , 2016, 74, 208-216.	3.0	30
43	Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 943-950.	0.5	30
44	Pulmonary involvement in antisyntetase syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 603-610.	2.0	29
45	Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity—a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 227-235.	2.9	27
46	Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. <i>Lupus</i> , 2015, 24, 507-515.	0.8	24
47	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021, 124, 102729.	3.0	23
48	How I treat idiopathic patients with inflammatory myopathies in the clinical practice. <i>Autoimmunity Reviews</i> , 2017, 16, 999-1007.	2.5	22
49	In-/off-label use of biologic therapy in systemic lupus erythematosus. <i>BMC Medicine</i> , 2014, 12, 30.	2.3	21
50	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1373-1385.	1.0	21
51	Lymphocyte immunophenotyping in inflammatory myositis: a review. <i>Current Opinion in Rheumatology</i> , 2021, 33, 522-528.	2.0	20
52	Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. <i>Autoimmunity Reviews</i> , 2018, 17, 11-18.	2.5	19
53	Rheumatic and autoimmune thyroid disorders: A causal or casual relationship?. <i>Autoimmunity Reviews</i> , 2015, 14, 57-63.	2.5	18
54	Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 176-177.	0.4	18

#	ARTICLE	IF	CITATIONS
55	17- $\beta$ -estradiol affects BlyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. <i>Lupus</i> , 2015, 24, 382-391.	0.8	17
56	Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. <i>Rheumatology</i> , 2022, 61, 688-695.	0.9	17
57	When to use belimumab in SLE. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 737-740.	1.3	16
58	Preclinical and early systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 1014-22.	1.4	16
59	Nonimmune mechanisms in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2020, 32, 515-522.	2.0	16
60	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , 2017, 16, 1119-1124.	2.5	13
61	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 472-489.	2.9	13
62	Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	13
63	Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. <i>Rheumatology</i> , 2021, 60, 1313-1320.	0.9	12
64	Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110406.	1.2	11
65	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2019, 10, 29.	2.2	10
66	Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. <i>Journal of Nephrology</i> , 2021, 34, 389-398.	0.9	9
67	Belimumab: a step forward in the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 563-573.	1.4	9
68	Vaccination of mice for research purpose: alum is as effective as and safer than complete Freund adjuvant. <i>Reumatismo</i> , 2012, 64, 380-7.	0.4	8
69	Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis. <i>Lupus Science and Medicine</i> , 2022, 9, e000689.	1.1	8
70	SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype. <i>Frontiers in Immunology</i> , 2018, 9, 2081.	2.2	7
71	Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings. <i>Journal of Autoimmunity</i> , 2020, 111, 102443.	3.0	7
72	IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2021, 124, 102725.	3.0	7

#	ARTICLE	IF	CITATIONS
73	Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab. <i>Frontiers in Immunology</i> , 2022, 13, 796508.	2.2	7
74	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014, 5, 95-100.	3.9	6
75	The olfactory function is impaired in patients with idiopathic inflammatory myopathies. <i>Immunologic Research</i> , 2014, 60, 247-252.	1.3	6
76	Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis. <i>Autoimmunity Reviews</i> , 2022, 21, 103018.	2.5	5
77	Unresolved and critical issues in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 1093-1095.	2.5	4
78	Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2022, 9, 852162.	1.2	4
79	Diagnostic and prognostic role of renal histopathology in rheumatic diseases. <i>Reumatismo</i> , 2018, 70, 165-177.	0.4	3
80	Physician's global assessment is often useful in SLE, but not always: the case of clinical remission. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-217611.	0.5	3
81	The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission. <i>Israel Medical Association Journal</i> , 2017, 19, 454-458.	0.1	3
82	Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion. <i>Autoimmunity Reviews</i> , 2018, 17, 1-3.	2.5	2
83	Deletions in VANGL1 are a risk factor for antibody-mediated kidney disease. <i>Cell Reports Medicine</i> , 2021, 2, 100475.	3.3	2
84	A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab – comments on article by Fredericks et Al.. <i>Lupus</i> , 2014, 23, 1445-1446.	0.8	1
85	FRIO199...EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY. , 2019, ,		1
86	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
87	The Influence of Dietary Intervention in Connective Tissue Diseases: Evidence from Randomized Clinical Trials. <i>Rheumato</i> , 2021, 1, 5-16.	0.2	1
88	Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 188-194.	0.4	1
89	Infections and Idiopathic Inflammatory Myopathies. , 2015, , 715-727.		0
90	Cardiac Involvement in Systemic Lupus Erythematosus. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 265-293.	0.1	0

#	ARTICLE	IF	CITATIONS
91	222â€¦Circulating pentraxin3-specific B cells are decreased in lupus nephritis. , 2019, , .		0
92	AB1289â€¦TESTING DIFFERENT ITEMS INCLUDED IN THE DEFINITION OF REMISSION IN A MULTICENTRE SLE COHORT. , 2019, , .		0
93	THU0224â€¦THE HEPATITIS VIRUS PRES1 PROTEIN RETARDS THE ONSET OF LUPUS-LIKE GLOMERULONEPHRITIS IN NZB/W F1 MICE. , 2019, , .		0
94	THU0685â€¦THE IMPACT OF ACHIEVEMENT OF RESPONSE AT ONE YEAR AFTER STARTING THERAPY ON THE LONG-TERM OUTCOME OF LUPUS NEPHRITIS. , 2019, , .		0
95	OP0247â€¦EFFECT OF IMMUNOSUPPRESSIVE DRUG WITHDRAWAL ON DAMAGE PROGRESSION AND FLARE OCCURRENCE IN SLE PATIENTS IN REMISSION. , 2019, , .		0
96	173â€¦Immunosuppressant discontinuation in systemic lupus erythematosus: prevalence, risk of subsequent flare and effect on damage accrual. , 2019, , .		0
97	P77â€¦Evaluation of disease activity at conception in a prospective cohort of SLE pregnancies. , 2020, , .		0